Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 -1.20%69 Net Debt Paydown Yield % is 0.53% as of Jul. 23, 2026, which is 253% above its 10-year median of 0.15. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円780.37 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 1,164 Biotechnology companies, CellSource Co ranks better than 67.96% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, CellSource Co's Net Debt Paydown Yield % was 0.53%.
CellSource Co (TSE:4880) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
CellSource Co Net Debt Paydown Yield % Related Terms
CellSource Co Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for CellSource Co's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, CellSource Co's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where CellSource Co's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.53% mean?
CellSource Co (TSE:4880) has a Net Debt Paydown Yield % of 0.53% as of Jul. 23, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on CellSource Co and its competitors. This is 253% above median its historical median of 0.15. Over the past decade, CellSource Co's Net Debt Paydown Yield % has ranged from 0.01 to 0.53. According to the industry distribution chart, CellSource Co ranks #373 out of 1164 companies in the Biotechnology industry, placing it in the top 32%.
Is CellSource Co's Net Debt Paydown Yield % too high?
CellSource Co's current Net Debt Paydown Yield % of 0.53% is 253% above median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.53. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. CellSource Co's value of 0.53% is 1666.7% above this industry median. Based on the distribution chart, CellSource Co ranks #373 out of 1164 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #373 out of 1164 companies for Net Debt Paydown Yield %. This puts CellSource Co in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.03. CellSource Co's value of 0.53% is 1666.7% above this benchmark. Historically, CellSource Co's own Net Debt Paydown Yield % has ranged from 0.01 to 0.53 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.03, CellSource Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,164 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current Net Debt Paydown Yield % of 0.53% is 1666.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current Net Debt Paydown Yield % is 0.53%, which is 253% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円780.37, compared to a current price of 円329.00 — trading 57.8% below its estimated fair value. The current Net Debt Paydown Yield % is 0.53%, which is 253% above median its 10-year median of 0.15 and 1666.7% above the Biotechnology industry median of 0.03. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Net Debt Paydown Yield % is 0.53% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円329.00 is trading 57.8% below its estimated GF Value™ of 円780.37.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Net Debt Paydown Yield %: 0.53% (253% above median its 10-year median of 0.15)
GF Value™: 円780.37 vs. price of 円329.00 (57.8% below fair value)
Industry Position: 1666.7% above the Biotechnology median (#373 of 1164)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
